Evidence map›Paper›PMID 35785462›Full record

ArticleChembiochem : a European journal of chemical biology2022

Synthetic α-Helical Peptides as Potential Inhibitors of the ACE2 SARS-CoV-2 Interaction.

Pascal M Engelhardt, Sebastián Florez-Rueda, Marco Drexelius, Jörg-Martin Neudörfl, Daniel Lauster, Christian P R Hackenberger, Ronald Kühne, Ines Neundorf, Hans-Günther Schmalz

Abstract read
In one paragraph

Article in Chembiochem : a European journal of chemical biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Synthetic α-Helical Peptides as Potential Inhibitors of the ACE2 SARS-CoV-2 Interaction.Chembiochem : a European journal of chemical biology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Pascal M EngelhardtDepartment of Chemistry, University of Cologne, Greinstrasse 4, 50939, Cologne, Germany.
Sebastián Florez-RuedaLeibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Strasse 10, 13125, Berlin, Germany.
Marco DrexeliusDepartment of Chemistry, University of Cologne, Zülpicher Straße 47a, 50674, Cologne, Germany.
Jörg-Martin NeudörflDepartment of Chemistry, University of Cologne, Greinstrasse 4, 50939, Cologne, Germany.ORCID 0000-0002-2918-0565
Daniel LausterFreie Universität Berlin, Institut für Biochemie und Chemie, Arnimallee 22, 14195, Berlin, Germany.ORCID 0000-0003-2009-633X
Christian P R HackenbergerLeibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Strasse 10, 13125, Berlin, Germany.ORCID 0000-0001-7457-4742
Ronald KühneLeibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Strasse 10, 13125, Berlin, Germany.
Ines NeundorfDepartment of Chemistry, University of Cologne, Zülpicher Straße 47a, 50674, Cologne, Germany.ORCID 0000-0001-6450-3991
Hans-Günther SchmalzDepartment of Chemistry, University of Cologne, Greinstrasse 4, 50939, Cologne, Germany.ORCID 0000-0003-0489-1827

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

During viral cell entry, the spike protein of SARS-CoV-2 binds to the α1-helix motif of human angiotensin-converting enzyme 2 (ACE2). Thus, alpha-helical peptides mimicking this motif may serve as inhibitors of viral cell entry. For this purpose, we employed the rigidified diproline-derived module ProM-5 to induce α-helicity in short peptide sequences inspired by the ACE2 α1-helix. Starting with Ac-QAKTFLDKFNHEAEDLFYQ-NH

Indexed as

Angiotensin-Converting Enzyme 2COVID-19 Drug TreatmentHumansPeptidesProtein BindingSARS-CoV-2Spike Glycoprotein, CoronavirusAngiotensin-Converting Enzyme 2PeptidesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2CD spectroscopypeptidesprotein-protein interactionsSARS-CoV-2secondary structures

Identifiers

PMID35785462
PMCPMC9350387

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.